Abstract
With the increasing availability of highly potent, pharmacologically active, and selective protein kinase inhibitors, identification of individuals who would benefit from targeted kinase inhibitors could facilitate application of precision medicine strategies for cancer therapy. A recent study by Kothari and colleagues reports preclinical studies that highlight the potential of targeting kinases with extreme expression for cancer precision medicine, warranting further clinical investigation of an individual-specific outlier kinase targeting approach.